---
schema_version: "secwatch.filing_event.v1"
accession: "0001386570-26-000017"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2026-03-19T23:59:59+00:00"
generated_at: "2026-05-15T09:35:53.117825+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Niagen Bioscience increases share repurchase authorization to $20M from $10M

## Summary
- Board approved increase of share repurchase program from $10M to $20M.
- Approximately $2.6M of common stock repurchased through March 17, 2026.
- Program runs through October 31, 2027, unless modified or terminated.
- CEO Rob Fried cited conviction in strategy and long-term value.

## SEC filing metadata
- accession: 0001386570-26-000017
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2026-03-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000138657026000017/0001386570-26-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000138657026000017/cdxc-20260319.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001386570-26-000017
- JSON: https://secwatch.observer/filing/0001386570-26-000017.json
- Plain text: https://secwatch.observer/filing/0001386570-26-000017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.